Loading
Latest filing published 19 Feb 2025 for Arbutus Biopharma Corp. Read the official filing
No signal scores available.
Michael J. McElhaugh is a declared insider of Arbutus Biopharma Corp, with filings sourced from SEC (Form 4). Between 1 February 2023 and 14 February 2025, the trades on record add up to 4 filings.
Sales make up the whole of the open-market record (1 sale, €76k). Other entries cover 3 share grants. In 2025 alone, the filings show no purchases and 1 sale.
The newest entry dates from 19 February 2025: a share grant, in Arbutus Biopharma Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations